Targeting apoptosis pathways for new cancer therapeutics

Annual Review of Medicine

Volumn 65, Issue , 2014, Pages 139-155

  Bai, Longchuan ^a   Wang, Shaomeng ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

BCL 2; BCL XL; CIAPs; MDM2; P53; XIAP

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 737 263 199; ANTINEOPLASTIC AGENT; AT 406; BCL2 RELATED PROTEIN A1; BENDAMUSTINE; BIRINAPANT; CASPASE 8; CGM 097; CUDC 427; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DEBIO 1143; GDC 0152; GDC 0917; HGS 1029; IRINOTECAN; ISOSORBIDE; LCL 161; MI 219; MI 77301; NAVITOCLAX; OBATOCLAX; PROTEIN BAK; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN MDMX; PROTEIN P53; RG 7112; RITUXIMAB; SM 406; UNCLASSIFIED DRUG; VENETOCLAX; WEHI 539;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BELL PALSY; BINDING AFFINITY; BONE MARROW TOXICITY; BREAST CANCER; CANCER THERAPY; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CYTOKINE PRODUCTION; DNA DAMAGE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE DELETION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; INFLAMMATORY BREAST CANCER; LARYNX CANCER; LEUKEMIA; LIPOSARCOMA; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; METASTASIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT RESPONSE; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION;

EID: 84901506759     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-010713-141310     Document Type: Review

References (100)

1. Cory S, Huang DC, Adams JM. 2003. The BCL-2 family: roles in cell survival and oncogenesis. Oncogene 22(53):8590-607 (Pubitemid 38028528)
2. Li Q, Lozano G. 2013. Molecular pathways: targeting MDM2 and MDM4 in cancer therapy. Clin. Cancer Res. 19(1):34-41
3. Letai A, Bassik MC, Walensky LD, et al. 2002. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2(3):183-92 (Pubitemid 41043974)
4. Kim H, Rafiuddin-Shah M, Tu HC, et al. 2006. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 8(12):1348-58 (Pubitemid 44835109)
5. Sattler M, Liang H, Nettesheim D, et al. 1997. Structure of BCL-XL-BAK peptide complex: recognition between regulators of apoptosis. Science 275(5302):983-86 (Pubitemid 27087715)
6. Souers AJ, Leverson JD, Boghaert ER, et al. 2013. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19(2):202-8
7. Oltersdorf T, Elmore SW, Shoemaker AR, et al. 2005. An inhibitor of BCL-2 family proteins induces regression of solid tumours. Nature 435(7042):677-81 (Pubitemid 40825512)
8. Zheng CH, Yang H, Zhang M, et al. 2012. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic BCL-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity. Bioorg. Med. Chem. Lett. 22(1):39-44
9. Tse C, Shoemaker AR, Adickes J, et al. 2008. ABT-263: a potent and orally bioavailable BCL-2 family inhibitor. Cancer Res. 68(9):3421-28
10. Lessene G, Czabotar PE, Sleebs BE, et al. 2013. Structure-guided design of a selective BCL-XL inhibitor. Nat. Chem. Biol. 9(6):390-97
11. Zhou H, Chen J, Meagher JL, et al. 2012. Design of BCL-2 and BCL-XL inhibitors with subnanomolar binding affinities based upon a new scaffold. J. Med. Chem. 55(10):4664-82
12. Chen J, Zhou H, Aguilar A, et al. 2012. Structure-based discovery of BM-957 as a potent smallmolecule inhibitor of BCL-2 and BCL-XL capable of achieving complete tumor regression. J. Med. Chem. 55(19):8502-14
13. Vogler M, Weber K, Dinsdale D, et al. 2009. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ. 16(7):1030-39
14. Tahir SK, Yang X, Anderson MG, et al. 2007. Influence of BCL-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 67(3):1176-83
15. Konopleva M, Contractor R, Tsao T, et al. 2006. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10(5):375-88 (Pubitemid 44693472)
16. Tahir SK, Wass J, Joseph MK, et al. 2010. Identification of expression signatures predictive of sensitivity to the BCL-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol. Cancer Ther. 9(3):545-57
17. Rooswinkel RW, van de Kooij B, Verheij M, et al. 2012. BCL-2 is a better ABT-737 target than BCL-XL or BCL-w and only Noxa overcomes resistance mediated by MCL-1, BFL-1, or BCL-B. Cell Death Dis. 3:e366
18. Merino D, Khaw SL, Glaser SP, et al. 2012. BCL-2, BCL-x(L), and BCL-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 119(24):5807-16
19. Ackler S, Mitten MJ, Foster K, et al. 2010. The BCL-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother. Pharmacol. 66(5):869-80
20. Chen J, Jin S, Abraham V, et al. 2011. The BCL-2/BCL-X(L)/BCL-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol. Cancer Ther. 10(12):2340-49
21. Shi J, Zhou Y, Huang HC, et al. 2011. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing BCL-XL. Cancer Res. 71(13):4518-26
22. Tan N, Wong M, Nannini MA, et al. 2013. BCL-2/BCL-XL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models. Mol. Cancer Ther. 12:853-64
23. Roberts AW, Seymour JF, Brown JR, et al. 2012. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30(5):488-96
24. Wilson WH, O'Connor OA, Czuczman MS, et al. 2010. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11(12):1149-59
25. Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al. 2011. Phase I study of navitoclax (ABT-263), a novel BCL-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 29(7):909-16
26. Zhang H, Nimmer PM, Tahir SK, et al. 2007. BCL-2 family proteins are essential for platelet survival. Cell Death Differ. 14(5):943-51 (Pubitemid 46655455)
27. Schoenwaelder SM, Jarman KE, Gardiner EE, et al. 2011. BCL-xL-inhibitory BH3mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 118(6):1663-74
28. Rudin CM, Hann CL, Garon EB, et al. 2012. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18(11):3163-69
29. Vandenberg CJ, Cory S. 2013. ABT-199, a new BCL-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 121(12):2285-88
30. Humerickhouse R. 2013. Remarkable early clinical activity with the BCL-2 selective inhibitor ABT-199: proving the concept. Presented at AACR Annu. Meet., Apr. 6-10, Washington, DC
31. Seymour JF, Davids MS, Pagel JM, et al. 2013. Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). J. Clin. Oncol. 31(Suppl.): abstr. 7018
32. Zhai D, Jin C, Satterthwait AC, et al. 2006. Comparison of chemical inhibitors of antiapoptotic BCL- 2-family proteins. Cell Death Differ. 13(8):1419-21 (Pubitemid 44057478)
33. Nguyen M, Marcellus RC, Roulston A, et al. 2007. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. USA 104(49):19512-17
34. Konopleva M, Watt J, Contractor R, et al. 2008. Mechanisms of antileukemic activity of the novel BCL-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 68(9):3413-20
35. Goard CA, Schimmer AD. 2013. An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evid. 8:15-26
36. Balakrishnan K, Wierda WG, Keating MJ, et al. 2008. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 112(5):1971-80
37. Liu G, Kelly WK, Wilding G, et al. 2009. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin. Cancer Res. 15(9):3172-76
38. Baggstrom MQ, Qi Y, Koczywas M, et al. 2011. A phase II study of AT-101 (Gossypol) in chemotherapysensitive recurrent extensive-stage small cell lung cancer. J. Thorac. Oncol. 6(10):1757-60
39. Heist RS, Fain J, Chinnasami B, et al. 2010. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J. Thorac. Oncol. 5(10):1637-43
40. Ready N, Karaseva NA, Orlov SV, et al. 2011. Double-blind, placebo-controlled, randomized phase II study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J. Thorac. Oncol. 6(4):781-85
41. Wong M, Tan N, Zha J, et al. 2012. Navitoclax (ABT-263) reduces BCL-X(L)-mediated chemoresistance in ovarian cancer models. Mol. Cancer Ther. 11(4):1026-35
42. Deng J, Carlson N, Takeyama K, et al. 2007. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12(2):171- 85 (Pubitemid 47199122)
43. Morales AA, Kurtoglu M, Matulis SM, et al. 2011. Distribution of BIM determines MCL-1 dependence or codependence with BCL-xL/BCL-2 in MCL-1-expressing myeloma cells. Blood 118(5):1329-39
44. Del Gaizo Moore V, Brown JR, Certo M, et al. 2007. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Invest. 117(1):112- 21 (Pubitemid 46048458)
45. Al-Harbi S, Hill BT, Mazumder S, et al. 2011. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood 118(13):3579-90
46. Bodet L, Gomez-Bougie P, Touzeau C, et al. 2011. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 118(14):3901-10
47. Du C, Fang M, Li Y, et al. 2000. SMAC, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102(1):33-42
48. Eckelman BP, Salvesen GS, Scott FL. 2006. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 7(10):988-94 (Pubitemid 44480512)
49. Varfolomeev E, Goncharov T, Fedorova AV, et al. 2008. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFα)-induced NF-κB activation. J. Biol. Chem. 283(36):24295-99
50. Bertrand MJ, Milutinovic S, Dickson KM, et al. 2008. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30(6):689-700 (Pubitemid 351818251)
51. Vallabhapurapu S, Matsuzawa A, Zhang W, et al. 2008. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling. Nat. Immunol. 9(12):1364-70
52. Zarnegar BJ, Wang Y, Mahoney DJ, et al. 2008. Noncanonical NF-κB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 9(12):1371-78
53. Fulda S, Vucic D. 2012. Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 11(2):109-24
54. Fulda S. 2008. Targeting inhibitor of apoptosis proteins (IAPs) for cancer therapy. Anticancer Agents Med. Chem. 8(5):533-39
55. Cheung HH, Mahoney DJ, Lacasse EC, et al. 2009. Down-regulation of c-FLIP enhances death of cancer cells by SMAC mimetic compound. Cancer Res. 69(19):7729-38
56. Varfolomeev E, Blankenship JW, Wayson SM, et al. 2007. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131(4):669-81 (Pubitemid 350087204)
57. Lu J, BaiL, Sun H, et al. 2008. SM-164: a novel, bivalentSMACmimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 68(22):9384-93
58. Ndubaku C, Varfolomeev E, Wang L, et al. 2009. Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem. Biol. 4(7):557-66
59. Flygare JA, Beresini M, Budha N, et al. 2012. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J. Med. Chem. 55(9):4101-13
60. Tolcher AW, Papadopoulos KP, Patnaik A, et al. 2013. Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma. J. Clin. Oncol. 31(Suppl.): abstr. 2503
61. Allensworth JL, Sauer SJ, Lyerly HK, et al. 2013. SMAC mimetic birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α- independent mechanism. Breast Cancer Res. Treat. 137(2):359-71
62. Amaravadi RK, Schilder RJ, Dy GK, et al. 2011. Phase 1 study of the SMAC mimetic TL32711 in adult subjects with advanced solid tumors and lymphoma to evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor activity. Proc. Annu. Meet. Am. Assoc. Cancer Res., 102nd, Orlando, FL, Apr. 2-6. Philadelphia, PA: AACR
63. Amaravadi RK, Senzer NN, Martin LP, et al. 2013. A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients. J. Clin. Oncol. 31(Suppl.): abstr. 2504
64. Senzer NN, LoRusso P, Martin LP, et al. 2013. Phase II clinical activity and tolerability of the SMACmimetic birinapant (TL32711) plus irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer. J. Clin. Oncol. 31(Suppl.): abstr. 3621
65. Sharma SK, Straub C, Zawel L. 2006. Development of peptidomimetics targeting IAPs. Int. J. Pept. Res. Ther. 12(1):21-32
66. Dienstmann R, Vidal L, Dees EC, et al. 2012. A phase Ib study of LCL161, an oral inhibitor of apoptosis (IAP) antagonist, in combination with weekly paclitaxel in patients with advanced solid tumors. Cancer Res. 72(Suppl. 24):P6-11-06
67. Houghton PJ, Kang MH, Reynolds CP, et al. 2012. Initial testing (stage 1) of LCL161, a SMACmimetic, by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 58(4):636-39
68. Sikic BI, Eckhardt SG, Gallant G, et al. 2011. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) ofHGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: results of a phase I study. J. Clin. Oncol. 29(Suppl.): abstr. 3008
69. Cai Q, Sun H, Peng Y, et al. 2011. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J. Med. Chem. 54(8):2714-26
70. Erickson RI, Tarrant J, Cain G, et al. 2013. Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-αpharmacology. Toxicol. Sci. 131(1):247-58
71. Feoktistova M, Geserick P, Kellert B, et al. 2011. cIAPs block ripoptosome formation, a RIP1/caspase- 8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol. Cell 43(3):449-63
72. Tenev T, Bianchi K, Darding M, et al. 2011. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol. Cell 43(3):432-48
73. Wagner L, Marschall V, Karl S, et al. 2013. SMAC mimetic sensitizes glioblastoma cells to temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner. Oncogene 32(8):988-97
74. Fridman JS, Lowe SW. 2003. Control of apoptosis by p53. Oncogene 22(56):9030-40 (Pubitemid 38121703)
75. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. 2004. Direct activation of BAX by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303(5660):1010-14 (Pubitemid 38209704)
76. Leu JI, Dumont P, Hafey M, et al. 2004. Mitochondrial p53 activates BAK and causes disruption of a BAK-MCL1 complex. Nat. Cell Biol. 6(5):443-50 (Pubitemid 38607505)
77. Mihara M, Erster S, Zaika A, et al. 2003. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11(3):577-90 (Pubitemid 36385115)
78. Momand J, Zambetti GP, Olson DC, et al. 1992. TheMDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69(7):1237-45
79. Oliner JD, Pietenpol JA, Thiagalingam S, et al. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362(6423):857-60 (Pubitemid 23132165)
80. Barak Y, Juven T, Haffner R, et al. 1993. MDM2 expression is induced by wild type p53 activity. EMBO J. 12(2):461-68 (Pubitemid 23073692)
81. Momand J, Jung D, Wilczynski S, et al. 1998. The MDM2 gene amplification database. Nucleic Acids Res. 26(15):3453-59 (Pubitemid 28347214)
82. Kussie PH, Gorina S, Marechal V, et al. 1996. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274(5289):948-53 (Pubitemid 26398409)
83. Vassilev LT, Vu BT, Graves B, et al. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659):844-48 (Pubitemid 38174664)
84. Tovar C, Rosinski J, Filipovic Z, et al. 2006. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. USA 103(6):1888-93 (Pubitemid 43228788)
85. Tovar C, Graves B, Packman K, et al. 2013. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res. 73(8):2587-97
86. Vu B, Wovkulich P, Pizzolato G, et al. 2013. Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development. ACS Med. Chem. Lett. 4(5):466-69
87. Ray-Coquard I, Blay JY, Italiano A, et al. 2012. Effect of the MDM2 antagonist RG7112 on the p53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 13(11):1133-40
88. Shangary S, Qin D, McEachern D, et al. 2008. Temporal activation of p53 by a specificMDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. USA 105(10):3933-38 (Pubitemid 351723502)
89. Montes de Oca Luna R, Wagner DS, Lozano G. 1995. Rescue of early embryonic lethality in MDM2- deficient mice by deletion of p53. Nature 378(6553):203-6
90. Jones SN, Roe AE, Donehower LA, et al. 1995. Rescue of embryonic lethality inMDM2-deficient mice by absence of p53. Nature 378(6553):206-8
91. Grier JD, Xiong S, Elizondo-Fraire AC, et al. 2006. Tissue-specific differences of p53 inhibition by MSM2 and MDM4. Mol. Cell. Biol. 26(1):192-98
92. Francoz S, Froment P, Bogaerts S, et al. 2006. MDM4 and MDM2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc. Natl. Acad. Sci. USA 103(9):3232-37 (Pubitemid 43346453)
93. Xiong S, Van Pelt CS, Elizondo-Fraire AC, et al. 2006. Synergistic roles of MDM2 andMDM4 for p53 inhibition in central nervous system development. Proc. Natl. Acad. Sci. USA 103(9):3226-31 (Pubitemid 43346452)
94. Liu D, Ou L, Clemenson GD Jr, et al. 2010. Puma is required for p53-induced depletion of adult stem cells. Nat. Cell Biol. 12(10):993-98
95. Terzian T, Wang Y, Van Pelt CS, et al. 2007. Haploinsufficiency ofMDM2andMDM4in tumorigenesis and development. Mol. Cell. Biol. 27(15):5479-85
96. Laurie NA, Donovan SL, Shih CS, et al. 2006. Inactivation of the p53 pathway in retinoblastoma. Nature 444(7115):61-66 (Pubitemid 44684754)
97. Wade M, Wong ET, Tang M, et al. 2006. HDMX modulates the outcome of p53 activation in human tumor cells. J. Biol. Chem. 281(44):33036-44 (Pubitemid 46036686)
98. Patton JT, Mayo LD, Singhi AD, et al. 2006. Levels of HDMX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 66(6):3169-76
99. Vaseva AV, Yallowitz AR, Marchenko ND, et al. 2011. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors. Cell Death Dis. 2:e156
100. Aziz MH, Shen H, Maki CG. 2011. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene 30(46):4678-86